Narcobarbital

Narcobarbital
Clinical data
ATC code
Identifiers
  • 5-(2-bromoprop-2-en-1-yl)-5-isopropyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H15BrN2O3
Molar mass303.156 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)NC(=O)C1(CC(\Br)=C)C(C)C)C
  • InChI=1S/C11H15BrN2O3/c1-6(2)11(5-7(3)12)8(15)13-10(17)14(4)9(11)16/h6H,3,5H2,1-2,4H3,(H,13,15,17) checkY
  • Key:WGMASVSHOSNKMF-UHFFFAOYSA-N checkY
  (verify)

Narcobarbital (Pronarcon) is a barbiturate derivative developed in 1932 by Carl Heinrich Friedrich Boedecker and Heinrich Gruber Schoneberg, assignors to the firm J. D. Riedel-E. de Haën AG, Berlin, Germany. Later, in 1937, may, was patented in United States.[1] It is an N-methylated derivative of propallylonal and has similar sedative effects. It is still used in veterinary medicine for inducing surgical anaesthesia.[2]

References

  1. ^ US 2080071, "Tri-substituted barbituric acid", issued 11 May 1937, assigned to J. D. Riedel-E. de Haën AG. 
  2. ^ Committee for Veterinary Medicinal Products (1999). "Position Paper on availability of Veterinary Medicines agreed on 17 March 1999" (PDF). The European Medicines Agency. pp. 3–8. Archived from the original (PDF) on 18 December 2014.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.